Vaccination in hemodialysis patients
The advent of renal replacement therapy has led to the emergence of a population of patients whose total medical care is relegated to the renal specialist. Nonnephrologists are frequently averse to assume the care of non-renal problems encountered in this population and the renal specialist is called upon to attend to a myraid of preventive and therapeutic needs. Their unique characteristics notwithstanding, patients on maintenance hemodialysis are subject to the common infectious diseases for which adult immunizations are now available. In fact, because of their altered immune status, they are more prone to suffer serious consequences and chronic sequelae of these infections. Influenza, pneumococcal, and hepatitis B vaccines have been shown to be efficacious and safe in the general population, but questions remain as to their efficacy in the renal patient. Successful immunization requires an optimally operative immune system. Depressed cellular and humoral immunity in uremic subjects may underlie the impairment in adequate response to immunization. A review of health care maintenance policies in dialysis centers during 1982 to 1983 found that 88% of units offered yearly influenza vaccines, 66% offered Pneumovax, and only 17% offered hepatitis B vaccine (1) . Underutilization of adult immunization may leave renal patients exposed to risks of serious morbidity and possible mortality. In this essay we will review the efficacy of the three common vaccines and their usefulness in the renal patient.
Influenza vaccine
In addition to its inherent morbidity, influenza often heralds the development of serious bacterial pulmonary infections, and renal transplant recipients are at increased risk for acute rejection following influenza (2) . The hemodialysis patient's response to influenza vaccination is generally quite good. The percentage of patients demonstrating a four-fold or greater rise in hemagglutinating-inhibiting antibody titers may be as high as 87% (3) . Patients with inadequate responses to initial vaccination may benefit from booster immunization (4), although antibody titers are not routinely obtained to identify non-responders. No serious side effects have been documented in any vaccinated patient. The safety and efficacy of this vaccine should encourage its wider use. The low incidence of nonresponders makes serologic testing for development of immunity not cost effective.
Pneumococcal vaccine
Pneumovax has been recommended for use in chronic diseases and in the elderly. Renal patients may also benefit from vaccination. Streptococcus pneumonaie is still the leading cause of community acquired bacterial pneumonia, and is associated with very high mortality when it is accompanied by septicemia or other extra-pulmonary manifestations. Splenectomy advocated prior to transplant in an attempt to improve graft survival, places the already immunocompromised patient at particular risk for overwhelming pneumococcal sepsis (5) . Protective antibody titers, albeit lower than control, have been achieved in 80% of chronic hemodialysis patients using the 14-valent vaccine (6, 7) . Antibody titers may be in the protective range for most capsular antigens but sometimes are subtherapeutic (6, 7) . Moreover, merely demonstrating antibody levels by radioimmunoassay may not be reflective of host immunity to the disease. As opsonizing antibodies may be more closely related to host defense their measurement by chemiluminscense techniques may be more informative. Although renal patients are able to mount adequate antibody responses to pneumococcal vaccination, the response is shortlived compared to healthy controls (8, 9) . A study prompted by the reappearance of pneumococcal disease in a group of renal patients vaccinated two years earlier, demonstrated a 65% decline in antibody levels over two years (9) . Revaccina-tion led to an increase in antibody but the levels achieved were lower than those obtained with initial vaccination (12) . No serious reaction to revaccination occurred, leading the investigators to recommend revaccination at two year intervals (9) .
In summary, renal patients are able to mount antibody responses to protective levels for many, but not all, penumococcal antigens. Renal transplant patients are best vaccinated prior to transplantation. Revaccination of renal patients at two year intervals appears to be beneficial and free of risk. Questions remain about the efficacy of the 23-valent vaccine which although containing nine additional antigens, provides each at a lower dose than the 14-valent vaccine.
Hepatitis B vaccine
Hemodialysis patients are screened regularly for hepatitis B and strict infection control measures for the hepatitis B surface antigen positive patient have provided good control of the disease. Hepatitis B vaccine, used with increasing frequency in high risk groups, has not been widely offered to renal patients. A survey of hemodialysis centers conducted from 1982-1983 found only 17% of centers offering the vaccine (1) . A second survey by the Center for Disease Control in 1983 showed that 71 % of centers offered the vaccine to staff, but of these only 43% offered the vaccine to patients (10) . Fifteen percent of the patients in the Center for Disease Control survey had evidence of previous hepatitis B infection, 3% being chronic carriers. (10) . Hepatitis B infection in uremic patients often has a subclincal presentation and leads to a chronic carrier state in up to 60% of those infected. Many of these carriers demonstrate high infectivity by the presence of hepatitis B e antigen (11) .
The reasons for underutilization of the vaccine in this population is not clear, but may involve the cost of the vaccine and its efficacy. Various protocols have been tried to determine the best means of producing immunity in the renal patient. The most common schedule consists of three 40f.l.g injections of the formalininactivated vaccine (Merck, Sharp, and Oohme) at 0, 1 and 6 months (in contrast the 20f.l.g dose used for the general population). This results in a response rate of about 60% in hemodialysis patients, compared to nearly 100% in healthy controls (11) (12) (13) . The titers achieved in hemodialysis patients are significantly lower than controls (11, 12) and decline more rapidly over time (14) . In one study of hemodialysis patients over 25 months the same number of hepatitis B infections occurred in the vaccinated and placebo control groups (12) . In dialysis patients, the 40f.l.g dose of the formalin-inactivated vaccine was no more effective than the 20f.l.g dose (15) , and shorter dosing schedule of injections at 0, 1 and 3 months resulted in significantly lower antibody titers in both dialysis patients and controls (16) .
In contrast, high doses of heat-inactivated vaccine (Institute Pasteur Production and Central Laboratory of the Netherlands) with injections at monthly intervals appear to increase response rates (14, 17) . The newer recombinant vaccine appears to result in comparable immunogenicity as the formalin-inactivated vaccine when both were given as 40f.l.g doses at 0, 1 and 6 months (18) . Lower doses (20f.l.g) of recombinant vaccine yield lower antibody titers in dialysis patients compared to 40f.l.g doses when given monthly for 6 injections (18) .
At present it is technically inadvisable to use the recombinant vaccine for renal patients, as its formulation requires four cc of fluid injected into the deltoid per 40f.l.g dose (19) . In cases where immediate protection against hepatitis B is desirable, particulary in patients beginning hemodialysis therapy, HBIG (hyperimmunoglobulin) can be administered at the time of the first vaccination without impairing subsequent response (11) . Booster immunizations are useful in some patients who are initially low responders, or patients whose antibody titers have declined with time (14, 16, 17) . Some investigators recommend checking antibody titers every six months in the second year and, if significantly declined, providing a booster injection at that time (14) . Other measures such as therapy with thymopentin, a synthetic immunomodulating agent, in conjunction with formalin-inactivated vaccine have yielded disappointing results (20, 21) . In an effort to predict which dialysis patients will respond favorably to vaccination, dinitrochlorobenzene (ONCB) skin testing has been used as a measure of cell mediated immunity (22) . Strong reactors to the ONCB testing responded as well as controls to either 20J,1g or 40J,1g doses, whereas weak reactors were not responsive to the 20J,1g dose and had a 47% response to the larger dose (22) .
Many of the hepatitis vaccine studies are hampered by control groups that are often significantly younger that the patients, as well as variations in the site of injection. Upper extremity injections appear to provide better responses than do gluteal sites (23) . Thus, the decreased response rates demonstrated in dialysis patients in some studies may not be entirely due to uremia.
In general, vaccination of the renal patient against hepatitis B appears to have some benefit with no risk. No serious side effects have been reported. Most dialysis patients will mount an antibody response which, although in lower titers, may protect them from infection and chronic carrier states. Booster immunizations should be considered routinely. The optimal initial vaccination schedule remains controversial. Although the initial cost of vaccination may seem high, the need for monthly screening tests for the develop-
